

## SCHRIFTENVERZEICHNIS

Prof. Dr. med. Susanna Hegewisch-Becker

### A) Originalarbeiten

1. [Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl H, Hegewisch-Becker S, Michl M, Stemmler HJ](#):  
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. *Ann Oncol*. 2010 Aug. 19. (Epub ahead of print)
2. [Trabach T, Reinacher-Schick A, Hegewisch-Becker S, Vanhoefer U, Frieling T, Lehnert L, Schmiegel W, Graeven U](#):  
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Onkologie*, 2010; 33(3):89-93. Epub 2010 Feb 23
3. [Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C](#):  
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Br J Cancer*. 2010 Feb 2; 102(3): 500-5. Epub 2010 Jan 12.
4. [Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D](#):  
Intraperitoneal VEGF –inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? *Oncologist* 2009 Dec; 14(12): 1242-51. Epub 2009 Dec. 11. Review.
5. [Gnjatic S, Cao Y, Reichelt U, Yekebas EF, Nölker C, Marx AH, Erbersdobler A, Nishikawa H, Hildebrandt Y, Bartels K, Horn C, Stahl T, Gout I, Filonenko V, Ling KI, Cerundolo V, Luetkens T, Ritter G, Friedrichs K, Leuwer R, Hegewisch-Becker S, Izbicki JR, Bokemeyer C, Old LJ, Atanackovic D](#):  
NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. *Int J Cancer*, 2010 Jul 15; 127(2):391-93.

6. [Boeck S, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler T, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Neugebauer S, Heinemann V.](#) Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the „Arbeitsgemeinschaft Internistische Onkologie“. *Anticancer Drugs*. 2010 Jan; 21(21):94-100.
7. [Hegewisch-Becker S, Vanhoefer U, Kubicka S, Pech M, Moehler M, Riess H, Hartmann JT, Malek N, Rödel C, Arnold D:](#) Palliative treatment for colorectal cancer. *Onkologie* 2009; 32 Suppl 2:13-6. Epub 2009 Jun 22. Review. German.
8. [Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D:](#) Chemokine CXCL 13 is overexpressed in the tumor tissue and in the peripheral blood of breast cancer patients. *Br J Cancer*. 2008 Sep 16;99(6):930-8.
9. [Atanackovic D, Cao Y, Kim JW, Brandl S, Thom I, Faltz C, Hildebrandt Y, Bartels K, de Weerth A, Hegewisch-Becker S, Hossfeld DK, Bokemeyer C:](#) The local cytokine and chemokine milieu within malignant effusions. *Tumour Biol*. 2008;29(2):93-104. Epub 2008 Jun 2.
10. [Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie:](#) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J. Clin Oncol*. 2008 Mar 20;26(9):1435-42.
11. [Lutz MP, Wilke H, Wagener DJ, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, Balleisen L, Joossens E, Jansen RL, Debois M, Bethe U, Praet M, Wils J, Van Cutsem E; European Organisation for Research and Treatment of Cancer Gastrointestinal Group; Arbeitsgemeinschaft Internistische Onkologie:](#) Weekly infusional high-dose fluorouracil (HD-FU) plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40593 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol*. 2007 Jun 20;25(18):2580-5.

12. [Atanackovic D, Pollok K, Faltz C, Boeters I, Jung R, Nierhaus A, Braumann K-M, Hossfeld DK, Hegewisch-Becker S:](#)  
High-temperature whole-body hyperthermia (WBH) causes a redistribution of naïve/memory T cell subtypes in patients with solid tumors. *Am J Physiol* 2006, 290, R 585-94
13. [Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, Hossfeld DK, Hegewisch-Becker S, Bokemeyer C, Leuwer R:](#)  
Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. *Cancer Biol Ther* 2006, Sep 9; 5 (Epub ahead of print)
14. [Hiddemann W, Kneba M, Dryling M, Schmith N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M:](#)  
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the german Low-Grade Lymphoma Study Group. *Blood* 2005, 106, 3725-3732
15. [Atanackovic D, Panse J, Schafhausen P, Faltz C, Bartels K, Boeters I, Hossfeld DK, Hegewisch-Becker S:](#)  
Peripheral T-cells of patients with B cell non-Hodgkin`s lymphoma show a shift in their memory status. *Leuk Res* 2005, 29, 1019-1027
16. [Nagorsgen D, Scheibenbogen C, Letsch A, Germer CT, Buhr HJ, Hegewisch-Becker S, Rivoltini L, Thiel E, Keilholz U:](#)  
T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. *J Transl Med* 2005, 19, 3-10
17. [Hildebrandt B, Hegewisch-Becker S, Kerner T, Nierhaus A, Bakhshandeh-Bath A, Janni W, Zumschlange R, Sommer H, Riess H, Wust P:](#)  
Current status of radiant whole-body hyperthermia at temperatures >41.5 degrees C and practical guidelines for the treatment of adults. The German Interdisciplinary Working Group of Hyperthermia. *Int J Hyperthermia* 2005, 21, 169-183
18. [Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummrl MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E:](#)  
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. *J Clin Oncol* 2004, 22, 658-663

19. [Tuinmann G, Hegewisch-Becker S, Zschaber R, Kehr A, Schulz J, Hossfeld DK:](#)  
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience. *Anticancer Drugs* 2004, 15, 575-579
20. [Atanackovic D, Block A, de Werth A, Faltz Ch, Hossfeld DK, Hegewisch-Becker S:](#)  
Characterization of effusion-infiltrating T-cells: benign versus malignant effusions. *Clin Cancer Res*, 2004, 10, 2600-2608
21. [Hegewisch-Becker S, Braun K, Otte M, Corovic A, Atanackovic D, Nierhaus A, Hossfeld DK, Pantel K:](#)  
Haematogenous spread of tumor cells in patients treated with whole body hyperthermia (WBH, 41.8°C) as an adjunct to chemotherapy. *Clin Cancer Res* 2003, 9, 2079-2084
22. [Atanackovic D, Brettner S, Hegewisch-Becker S:](#)  
Pleural effusion of a second neoplasm in a patient with B-CLL: Two immunological compartments. *Am J Hematol* 2003, 73, 184-189
23. [Einsele H, Bamberg M, Budach W, Schmidberger H, Hess CF, Wormann B, Meisner C, Straka C, Hebart H, Trumper L, Kroger N, Zander A,R, Hegewisch-Becker S, Hossfeld DK, Schmidt H, Muller P, Schlimok G, Hertenstein B, Peest D, Metzner B, Frickhofen N, Kanz L, Bensinger WI:](#)  
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamid followed by autologous PBSCT in patients with advanced multiple myeloma. *Bone Marrow Transplant* 2003, 32, 593-599
24. [Bakshandeh A, Bruns I, Traynor A, Robins HI, Eberhardt K, Demedts A, Kaukel E, Koschel E, Gatzemeier U, Kohlmann Th, Dahlhoff K, Ehlers EM, Gruber Y, Zumschlinge R, Hegewisch-Becker S, Peters SO, Wiedemann GJ:](#)  
Ifosfamide, Carboplatin and Etoposide Combined with 41.8°C Whole Body Hyperthermia for Malignant Pleural Mesothelioma. *Lung Cancer* 2003 39, 339-345
25. [Langer F, Bergmann F, Budde U, Hegewisch-Becker S, Hossfeld DK:](#)  
Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. *Br J Haematol* 2002, 118, 271-274
26. [Langer F, Eifrig B, Marx G, Stork A, Hegewisch-Becker S, and Hossfeld DK:](#)  
Exacerbation of antiphospholipid antibody syndrome after surgical resection of localized cancer: a report of two cases. *Ann Haematol* 2002, 81, 727-731

27. [Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, Hegewisch-Becker S:](#)  
41.8 °C whole-body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases. *J Cancer Immunol Immunother* 2002, 51, 603-613
28. [Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmeier U, Atanackovic D, Nierhaus A, Hossfeld DK:](#)  
Whole body hyperthermia (41.8 °C) combined with bimonthly oxaliplatin, high dose leucovorin and 5-Fluorouracil 48h-continuous infusion in pretreated metastatic colorectal cancer: A phase II study. *Ann Oncol* 2002, 13; 1197-1204.
29. [Tuinmann G, Schilling G, Brettner S, Hegewisch-Becker S, Hossfeld DK:](#)  
Darminvagination als Folge einer intraabdominellen Manifestation eines großzelligen Non-Hodgkin-Lymphoms. *Med Welt* 2002; 53: 29-31
30. [Langer F, Eifrig B, Marx G, Stork A, Hegewisch-Becker S, and Hossfeld DK:](#)  
Exacerbation of antiphospholipid antibody syndrome after surgical resection of localized cancer: a report of two cases. *Ann Haematol* 2002, 81, 727-731
31. [Langer F, Bergmann F, Budde U, Hegewisch-Becker S, Hossfeld DK:](#)  
Prolonged inhibition of von Willebrand factor cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. *Br J Haematol* 2002; 118; 271-274
32. [Sagowski C, Jaehne M, Kehrl W, Hegewisch-Becker S, Wenzel S, Panse J, Nierhaus A:](#)  
Tumor oxygenation under combined whole-body-hyperthermia and polychemotherapy in a case of recurrent carcinoma of the oral cavity. *Eur Arch Otorhinolaryngol* 2002; 259: 27-31
33. [Carpinteiro A, Peinert S, Ostertag W, Zander AR, Hossfeld DK, Kühlcke K, Eckert HG, Baum C, Hegewisch-Becker S:](#)  
Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice. *Int J Cancer* 2002, 98; 785-792
34. [Wolf G, Krenz I, Hegewisch-Becker S, Hossfeld DK, Helmchen U, Stahl R:](#)  
Necrotizing glomerulonephritis associated with Hodgkin's disease. *Nephrol Dial Transplant* 2001; 16: 187-188

35. [Schilling G, Lipp R, Hegewisch-Becker S, Hossfeld DK:](#)  
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer. *Oncology (Huntingt)* 2000; 14 (Suppl 9): 38-40
36. [Sagowski C, Kehrl W, Hegewisch-Becker S, Wenzel S, Jaehnke M, Panse J, Nierhaus A:](#)  
Tumoroxxygenierung unter kombinierter Ganzkörperhyperthermie und Polychemotherapie. *HNO* 48:949-954, 2000
37. [Zornig C, Emmermann A, Hegewisch-Becker S, Peiper M:](#)  
Laparoskopische Splenektomie bei der idiopathischen Thrombozytopenie. *Dtsch Med Wochenschr*, 125: 452-454, 2000
38. [Wiedemann GJ, Zschaber R, Hegewisch-Becker S, Reichard P, Weber K, Uthgenannt D, Löwenstrom O, Jäger E, Freund M, Seeger R, Feller AC, Hartlapp JH, Wagner T, Illiger HJ:](#)  
Two oral Trofosamid Schedules in Elderly Patients with refractory Non-Hodgkin's Lymphoma. *Onkologie*; 22: 134-138, 1999
39. [Kröger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR:](#)  
Current options in the treatment of anthracycline-resistant breast cancer. *Cancer Treat Rev*, 25: 279-291, 1999
40. [Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl R:](#)  
Hyperuricemia and renal insufficiency associated with malignant disease: Urate Oxidase as an efficient Therapy? *Am J Kidney Diseases*, 34: E20, 1999
41. [Kröger N, Stockschläder M, Krüger W, Hegewisch-Becker S, Fuchs N, Rüssmann B, Renges H, Dürken M, Bielack S, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander AR:](#)  
Intensified conditioning regimen in bone marrow transplantation for philadelphia chromosome positive acute lymphoblastic leukemia. *Bone Marrow Transplantation*, 22: 1029-1033, 1998
42. [Hildinger M, Fehse B, Hegewisch-Becker S, John J, Rafferty JR, Ostertag W, Baum C:](#)  
Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-expression vectors. *Hum Gen Ther*, 9: 33-42, 1998
43. [Hegewisch-Becker S, Staib F, Löning T, Pichlmeier U, Kröger N, Reymann A, Hossfeld DK:](#)  
No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. *Ann Oncol*, 9: 85-93, 1998

44. [Eckert H-G, Stockschräder M, Just U, Hegewisch-Becker S, Grez M, Uhde A, Zander A, Ostertag W, Baum Ch:](#)  
High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral Vectors. *Blood*, 88: 3407-3415, 1996
45. [Hegewisch-Becker S, Hossfeld DK:](#)  
The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. *Ann Hematol*, 72: 105-117, 1996
46. [Hegewisch-Becker S, Faltz C, Hossfeld DK:](#)  
Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukemic cells. *Eur J Haematol*, 56: 12-22, 1996
47. [Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Körbling M, Andreeff M, Mechetner E, Roninson I, Giles R, Berenson R, Heimfeld S, Deisseroth AB:](#)  
Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus which contains the MDR1 chemotherapy resistance gene. *Gene Therapy*, 2: 285-294, 1995
48. [Baum C, Hegewisch-Becker S, Eckert H-G, Stocking C, Ostertag W:](#)  
Novel retroviral vectors for efficient expression of the multidrug resistance (mdr1) gene in early hematopoietic cells. *J. Virol.* 69: 7541-7547, 1995
49. [Stockschräder M, Hegewisch-Becker S, Krüger W, tom Dieck A, Hoffknecht M, Berger C, Kohlschütter B, Martin H, Peters S, Kabisch H, Kuse R, Weh H, Zander A:](#)  
Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. *Bone Marrow Transplant*, 16: 663-667, 1995
50. [Peters SO, Stockschräder M, Hegewisch-Becker S, Krüger W, Weh HJ, Hossfeld DK, Zander AR:](#)  
Infusion of tumor contaminated bone marrow for autologous rescue after high-dose therapy leading to long-term remission in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. *Bone Marrow Transplant* 15, 783-784, 1995
51. [Hegewisch-Becker S, Hanania EG, Fu S, Körbling M, Deisseroth AB, Andreeff M:](#)  
Transduction of MDR1 into human and mouse hematopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. *Br J Haematol*, 90: 876-883, 1995

52. [Baum C, Forster P, Hegewisch-Becker S, Harbers K:](#)  
An optimized electroporation protocol applicable to a wide range of cell lines. *Biotechniques*, 17: 1058-1062, 1994
53. [Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M:](#)  
Flow cytometric detection of the multidrug resistant phenotype in acute leukemia. *Cytometry*, 17: 84-93, 1994
54. [Fiedler W, Weh HJ, Hegewisch-Becker S, Hossfeld DK:](#)  
GCSF Gene is expressed but not rearranged in a patient with isochromosome 17q positive acute nonlymphocytic leukemia. *Cancer Genet Cytogenet*, 68: 49-51, 1993
55. [Kapaun P, Kabisch H, Held KR, Walter TA, Hegewisch S, Zander AR:](#)  
Atypical chronic myelogenous leukemia in a patient with trisomy 8 mosaicism syndrome. *Ann Hematol*, 66: 57-58, 1993
56. [Hegewisch-Becker S, Fliegner M, Tsuruo T, Zander A, Zeller W, Hossfeld DK:](#)  
P-glycoprotein expression in normal and reactive bone marrows. *Br J Cancer*, 67: 430-435, 1993
57. [Hegewisch-Becker S, Fliegner M, Tsuruo T, Zeller W, Hossfeld DK:](#)  
Multidrug resistance (mdr1) in adult leukemia at diagnosis: correlation with response to induction therapy. *Onkologie*, 16: 264-269, 1993.
58. [Hegewisch-Becker S, Szudra A, Hossfeld DK:](#)  
Exposure to lipophilic industrial solvents leads to increased P-glycoprotein expression in peripheral blood cells. *Br J Haematol*, 85: 220-222, 1993
59. [Hegewisch S, Weh HJ, Hossfeld DK:](#)  
TNF induced cardiomyopathy. *Lancet*, 335: 294-295, 1990.
60. [Redner A, Hegewisch-Becker S, Haimi J, Steinherz P, Andreeff M:](#)  
A study of multidrug resistance and cell kinetics in a child with near haploid acute lymphoblastic leukemia. *Leuk Res*, 14: 771-777, 1990.
61. [Hegewisch S, Mainzer K, Braumann D:](#)  
IgE Myelomatosis. *Blut (weitergeführt als Ann Hematol)*, 55: 55-66, 1987
62. [Koepp P, Hegewisch S:](#)  
Effects of guar on plasma viscosity and related parameters in diabetic children. *Eur J Pediatr* 137, 31-33, 1981.

63. [Koepp P, Hegewisch S:](#)  
Effects of guar and pectin on plasma viscosity and some other parameters in diabetic children. *Pediatr Adolesc Endocr*, 9: 15-19, 1981